CNSX:CNFA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

CanaFarma Hemp Products Corp. operates in the hemp industry that offers a range of hemp-related products and services. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has CanaFarma Hemp Products's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CNFA is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: CNFA's weekly volatility has decreased from 52% to 17% over the past year, but is still higher than 75% of Canadian stocks.


Market Performance


7 Day Return

-2.4%

CNFA

9.2%

CA Pharmaceuticals

2.8%

CA Market


1 Year Return

n/a

CNFA

14.8%

CA Pharmaceuticals

-0.3%

CA Market

Return vs Industry: Insufficient data to determine how CNFA performed against the Canadian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how CNFA performed against the Canadian Market.


Shareholder returns

CNFAIndustryMarket
7 Day-2.4%9.2%2.8%
30 Day-3.5%30.1%10.0%
90 Day-37.9%29.9%5.7%
1 Yearn/a14.8%14.8%3.3%-0.3%
3 Yearn/a-31.8%-32.9%12.2%1.3%
5 Yearn/a268.2%265.3%49.1%26.2%

Long-Term Price Volatility Vs. Market

How volatile is CanaFarma Hemp Products's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is CanaFarma Hemp Products undervalued compared to its fair value and its price relative to the market?

7.71x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CNFA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CNFA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CNFA is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.

PE vs Market: CNFA is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CNFA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CNFA is overvalued based on its PB Ratio (7.7x) compared to the CA Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is CanaFarma Hemp Products forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

60.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CanaFarma Hemp Products has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has CanaFarma Hemp Products performed over the past 5 years?

4.9%

Historical Pharmaceuticals & Biotech annual earnings growth


Earnings and Revenue History

Quality Earnings: CNFA is currently unprofitable.

Growing Profit Margin: CNFA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if CNFA's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare CNFA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CNFA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-45%).


Return on Equity

High ROE: CNFA has a negative Return on Equity (-83.46%), as it is currently unprofitable.


Next Steps

Financial Health

How is CanaFarma Hemp Products's financial position?


Financial Position Analysis

Short Term Liabilities: CNFA's short term assets ($3.9M) exceed its short term liabilities ($484.7K).

Long Term Liabilities: CNFA has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: CNFA is debt free.

Reducing Debt: CNFA has not had any debt for past 5 years.

Debt Coverage: CNFA has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CNFA has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is CanaFarma Hemp Products's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CNFA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CNFA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CNFA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CNFA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CNFA's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

David Lonsdale (66 yo)

no data

Tenure

Mr. David Martin Lonsdale serves as Chief Executive Officer of CanaFarma Hemp Products Corp. Mr. Lonsdale is a Director at Buchans Wileys Exploration Inc. He serves as CEO of Buchans Wileys Exploration Inc...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: CNFA only recently listed within the past 12 months.


Top Shareholders

Company Information

CanaFarma Hemp Products Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CanaFarma Hemp Products Corp.
  • Ticker: CNFA
  • Exchange: CNSX
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$70.439m
  • Shares outstanding: 195.66m
  • Website: https://www.canafarmacorp.com

Location

  • CanaFarma Hemp Products Corp.
  • 2080-777 Hornby Street
  • Vancouver
  • British Columbia
  • V6Z 1S4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CNFACNSX (Canadian National Stock Exchange)YesCommon SharesCACADMar 2020
4K9DB (Deutsche Boerse AG)YesCommon SharesDEEURMar 2020

Biography

CanaFarma Hemp Products Corp. operates in the hemp industry that offers a range of hemp-related products and services. It provides hemp-processing services and hemp-based products. The company is based in ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/27 01:03
End of Day Share Price2020/11/26 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.